FDA Review Puts Rezolute’s Genetic Disorder Drug Path In Question

All NewsMarch 24, 2026

Rezolute shares rise after FDA feedback on sunRIZE trial; mixed efficacy, data review ahead for rare genetic disorder drug.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent